These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29104319)

  • 1. Cytochrome
    Stiborová M; Indra R; Frei E; Kopečková K; Schmeiser HH; Eckschlager T; Adam V; Heger Z; Arlt VM; Martínek V
    Monatsh Chem; 2017; 148(11):1983-1991. PubMed ID: 29104319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NADPH- and NADH-dependent metabolism of and DNA adduct formation by benzo[
    Stiborová M; Indra R; Moserová M; Šulc M; Hodek P; Frei E; Schmeiser HH; Arlt VM
    Monatsh Chem; 2016; 147():847-855. PubMed ID: 27110038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of hepatic cytochrome b
    Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases.
    Stiborová M; Indra R; Moserová M; Cerná V; Rupertová M; Martínek V; Eckschlager T; Kizek R; Frei E
    Chem Res Toxicol; 2012 May; 25(5):1075-85. PubMed ID: 22390216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
    Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
    Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
    Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E
    Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine.
    Sulc M; Mrizova I; Cerna T; Frei E; Eckschlager T; Adam V; Kopeckova K; Stiborova M
    Neuro Endocrinol Lett; 2016 Dec; 37(Suppl1):95-102. PubMed ID: 28263536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NADH:Cytochrome b5 Reductase and Cytochrome b5 Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[a]pyrene.
    Stiborová M; Indra R; Moserová M; Frei E; Schmeiser HH; Kopka K; Phillips DH; Arlt VM
    Chem Res Toxicol; 2016 Aug; 29(8):1325-34. PubMed ID: 27404282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
    Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
    Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.
    Stiborová M; Černá V; Moserová M; Mrízová I; Arlt VM; Frei E
    Int J Mol Sci; 2014 Dec; 16(1):284-306. PubMed ID: 25547492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5.
    Inui H; Maeda A; Ohkawa H
    Biochemistry; 2007 Sep; 46(35):10213-21. PubMed ID: 17691855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy.
    Kotrbová V; Mrázová B; Moserová M; Martínek V; Hodek P; Hudeček J; Frei E; Stiborová M
    Biochem Pharmacol; 2011 Sep; 82(6):669-80. PubMed ID: 21683692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of human cytochrome P450 1A1-catalysed oxidation of benzo[
    Stiborová M; Indra R; Moserová M; Bořek-Dohalská L; Hodek P; Frei E; Kopka K; Schmeiser HH; Arlt VM
    Monatsh Chem; 2017; 148(11):1959-1969. PubMed ID: 29104317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes.
    Yamazaki H; Nakano M; Imai Y; Ueng YF; Guengerich FP; Shimada T
    Arch Biochem Biophys; 1996 Jan; 325(2):174-82. PubMed ID: 8561495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
    Stiborová M; Borek-Dohalská L; Aimová D; Kotrbová V; Kukacková K; Janouchová K; Rupertová M; Ryslavá H; Hudecek J; Frei E
    Gen Physiol Biophys; 2006 Sep; 25(3):245-61. PubMed ID: 17197724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation and detoxification metabolism of urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone by rat and mouse hepatic microsomes.
    Stiborova M; Cechova T; Borek-Dohalska L; Moserova M; Frei E; Schmeiser HH; Paca J; Arlt VM
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():8-15. PubMed ID: 23353838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
    Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
    Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.
    Stiborová M; Poljaková J; Ryslavá H; Dracínský M; Eckschlager T; Frei E
    Int J Cancer; 2007 Jan; 120(2):243-51. PubMed ID: 17066455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice.
    Stiborova M; Cerna V; Moserova M; Arlt VM; Frei E
    Neuro Endocrinol Lett; 2013; 34 Suppl 2():43-54. PubMed ID: 24362092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes.
    Yamazaki H; Nakano M; Gillam EM; Bell LC; Guengerich FP; Shimada T
    Biochem Pharmacol; 1996 Jul; 52(2):301-9. PubMed ID: 8694855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.